SECURITIES AND EXCHANGE COMMISSION
450 Fifth Street, N.W.
Washington, D.C. 20549
FORM 8-K/A-1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report: October 2, 1995
Golden Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
Colorado 0-9065 84-0645174
(State of (Commission (IRS Employer
incorporation) File Number) Identification No.)
1313 Washington Avenue, Golden, Colorado 80401
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (303) 279-
9375
Not Applicable
(Former Name or Former Address, if Change Since Last Report)
Item 8. Change In Fiscal Year.
On October 2, 1995, the Registrant elected to change its
fiscal year from September 1 through August 31 in each year to
January 1 through December 31 in each year. Subsequently, the
Registrant was informed by its independent auditors that the change
would cause a substantial portion of its net operating loss
carryforward to expire unused since the short tax year would be
considered a taxable year in the carryforward period. As a result,
on November 11, 1995, the Board of Directors of the Registrant
unanimously approved a proposal to retain its current fiscal year
of September 1 to August 31 in each year.
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
GOLDEN PHARMACEUTICALS, INC.
Date: November __, 1995 by:
Glen H. Weaver, Vice President
of Finance
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
GOLDEN PHARMACEUTICALS, INC.
Date: November __, 1995 By:
/s/ Glen H. Weaver
Glen H. Weaver, Vice President
of Finance
